drugset
drugset / Trial / NCT02039323

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

NCT02039323 ↗

Phase 1 Completed 6 enrolled University of North Carolina, Chapel Hill
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine the feasibility of a novel method to assess antiretroviral efficacy for protection against HIV-1 infection in vaginal and cervical tissue biopsies.

Timeline

Start
2014-02
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 600 mg Oral
Subject Tenofovir Small molecule 600 mg Oral

Indications

No indication recorded.